OncoMatch/Clinical Trials/NCT06297941
Study of REM-422 in Patients With AML or Higher Risk MDS
Is NCT06297941 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies REM-422 for myelodysplastic syndromes.
Treatment: REM-422 — The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hematopoietic stem cell transplantation
Exception: allowed if >60 days before first dose and not receiving immunosuppressive therapy post HSCT at screening, and no GVHD requiring systemic treatment (topical steroids for skin GVHD permitted)
Has undergone hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of REM-422 or is receiving immunosuppressive therapy post HSCT at the time of screening, or has GVHD requiring systemic treatment (topical steroids for ongoing skin GVHD is permitted).
Cannot have received: radiation therapy
Radiation therapy ≤ 7 days prior to the start of REM-422.
Cannot have received: investigational treatment
Receiving any other investigational treatment for any indication ≤ 3 weeks prior to enrollment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Moffitt Cancer Center · Tampa, Florida
- Massachusetts General Hospital · Boston, Massachusetts
- Memorial Sloan Kettering · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify